The presence of obesity and hyperglycaemia in patients with colon adenocarcinoma clinical stage (CS) I-III is linked with increased mortality risk and reduced disease-free survival (DFS), according to new research presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2019.
In a bid to determine the implications of obesity and hyperglycaemia on DFS and overall survival (OS), researchers examined data on 715 patients with CS I-III adenocarcinoma of the colon. All of the patients were treated with surgery+/-adjuvant chemotherapy.
A total of 45 per cent (n=323) of patients presented with obesity/overweight, while hyperglycaemia was observed in 57 per cent (n=406) of patients.
The study found patients with hyperglycaemia had a five-year DFS of 66 per cent versus 80 per cent for normoglycaemic patients (P=.001). Comparing body weight, five-year DFS was 72 per cent in both obesity/overweight and normal weight groups (P=.694).
Patients with hyperglycaemia had a five-year OS of 73 per cent versus 83 per cent for patients with normoglycaemia (P=.047). Patients with obesity/overweight had a five-year OS of 67 per cent versus 86 per cent for patients with normoweight (P=.001).